伐尼克兰短缺的临床后果:法国国家药物警戒数据库的研究。

IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Therapie Pub Date : 2025-03-05 DOI:10.1016/j.therap.2025.02.009
Amélie Lepert, Delphine Bourneau-Martin, Bénédicte Lebrun-Vignes, Alexandra Gentil, Pierre Brunel, Ivan Berlin, Marie Briet
{"title":"伐尼克兰短缺的临床后果:法国国家药物警戒数据库的研究。","authors":"Amélie Lepert, Delphine Bourneau-Martin, Bénédicte Lebrun-Vignes, Alexandra Gentil, Pierre Brunel, Ivan Berlin, Marie Briet","doi":"10.1016/j.therap.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Varenicline is a smoking cessation therapy included in the World Health Organization (WHO) model list of essential medicines. In May 2021, the presence of N-nitroso-varenicline, a carcinogenic agent, was detected in varenicline tablets above the limits determined by the European Medicine Agency (EMA), leading to batches being recalled and causing a shortage of this drug. The aim of this study was to use pharmacovigilance data to evaluate the clinical consequences of the shortage of varenicline.</p><p><strong>Methods: </strong>Data were extracted from the French PharmacoVigilance Database using the following terms: \"varenicline (tartrate of)\", \"varenicline\" and \"tartrate of varenicline\" as the suspected, interactive, or concomitant medication from 4 April 2021 to 17 March 2023. Each case was reviewed by a pharmacovigilance expert to select only cases that involved a varenicline shortage.</p><p><strong>Results: </strong>Among the 32 included cases, the reported adverse effects were: smoking relapse (n=21), tobacco cessation failure (n=7) and tobacco withdrawal syndrome (n=2). Most of the patients presented a high level of tobacco dependence. Before the introduction of varenicline, these smokers consumed a median of 20 cigarettes per day. They did not smoke while receiving varenicline. After the shortage, the daily cigarette consumption went up to 10 in all patients treated with nicotine replacement therapy (NRT) and up to 20 when NRT was not used.</p><p><strong>Discussion: </strong>In the context of a varenicline shortage, the pharmacovigilance data confirmed the risk of smoking relapse and/or cessation failure in patients with a strong addiction to cigarettes. Given the role of smoking exposure in respiratory, cancer and cardiovascular risk, it is vitally important that the availability of this medicine is ensured. Solutions, such as the importation of alternatives produced by other brands that pass the tests for impurity quantification, may prevent the risk in this context.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database.\",\"authors\":\"Amélie Lepert, Delphine Bourneau-Martin, Bénédicte Lebrun-Vignes, Alexandra Gentil, Pierre Brunel, Ivan Berlin, Marie Briet\",\"doi\":\"10.1016/j.therap.2025.02.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Varenicline is a smoking cessation therapy included in the World Health Organization (WHO) model list of essential medicines. In May 2021, the presence of N-nitroso-varenicline, a carcinogenic agent, was detected in varenicline tablets above the limits determined by the European Medicine Agency (EMA), leading to batches being recalled and causing a shortage of this drug. The aim of this study was to use pharmacovigilance data to evaluate the clinical consequences of the shortage of varenicline.</p><p><strong>Methods: </strong>Data were extracted from the French PharmacoVigilance Database using the following terms: \\\"varenicline (tartrate of)\\\", \\\"varenicline\\\" and \\\"tartrate of varenicline\\\" as the suspected, interactive, or concomitant medication from 4 April 2021 to 17 March 2023. Each case was reviewed by a pharmacovigilance expert to select only cases that involved a varenicline shortage.</p><p><strong>Results: </strong>Among the 32 included cases, the reported adverse effects were: smoking relapse (n=21), tobacco cessation failure (n=7) and tobacco withdrawal syndrome (n=2). Most of the patients presented a high level of tobacco dependence. Before the introduction of varenicline, these smokers consumed a median of 20 cigarettes per day. They did not smoke while receiving varenicline. After the shortage, the daily cigarette consumption went up to 10 in all patients treated with nicotine replacement therapy (NRT) and up to 20 when NRT was not used.</p><p><strong>Discussion: </strong>In the context of a varenicline shortage, the pharmacovigilance data confirmed the risk of smoking relapse and/or cessation failure in patients with a strong addiction to cigarettes. Given the role of smoking exposure in respiratory, cancer and cardiovascular risk, it is vitally important that the availability of this medicine is ensured. Solutions, such as the importation of alternatives produced by other brands that pass the tests for impurity quantification, may prevent the risk in this context.</p>\",\"PeriodicalId\":23147,\"journal\":{\"name\":\"Therapie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.therap.2025.02.009\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.therap.2025.02.009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:伐尼克兰是一种被列入世界卫生组织(世卫组织)基本药物标准清单的戒烟疗法。2021年5月,在伐尼克兰片剂中检测到致癌物质n -亚硝基-伐尼克兰,其含量超过了欧洲药品管理局(EMA)确定的限量,导致批次被召回,并造成该药短缺。本研究的目的是利用药物警戒数据来评估伐尼克兰短缺的临床后果。方法:从法国药物警戒数据库中提取数据,使用以下术语:“varenicline(酒石酸盐)”、“varenicline”和“varenicline的酒石酸盐”作为2021年4月4日至2023年3月17日的疑似、相互作用或伴随用药。每个病例都由药物警戒专家审查,以选择仅涉及伐尼克兰短缺的病例。结果:32例纳入病例中,报告的不良反应为:吸烟复发(n=21),戒烟失败(n=7),烟草戒断综合征(n=2)。大多数患者表现出高度的烟草依赖。在使用伐尼克兰之前,这些吸烟者平均每天吸烟20支。他们在服用伐仑克林时没有吸烟。在短缺之后,所有接受尼古丁替代疗法(NRT)的患者每天的香烟消费量增加到10支,而不使用NRT的患者则增加到20支。讨论:在varenicline短缺的背景下,药物警戒数据证实了重度烟瘾患者吸烟复发和/或戒烟失败的风险。鉴于吸烟暴露在呼吸道、癌症和心血管风险中的作用,确保这种药物的可得性至关重要。解决办法,例如进口通过杂质定量检测的其他品牌生产的替代品,可以防止这种情况下的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database.

Objectives: Varenicline is a smoking cessation therapy included in the World Health Organization (WHO) model list of essential medicines. In May 2021, the presence of N-nitroso-varenicline, a carcinogenic agent, was detected in varenicline tablets above the limits determined by the European Medicine Agency (EMA), leading to batches being recalled and causing a shortage of this drug. The aim of this study was to use pharmacovigilance data to evaluate the clinical consequences of the shortage of varenicline.

Methods: Data were extracted from the French PharmacoVigilance Database using the following terms: "varenicline (tartrate of)", "varenicline" and "tartrate of varenicline" as the suspected, interactive, or concomitant medication from 4 April 2021 to 17 March 2023. Each case was reviewed by a pharmacovigilance expert to select only cases that involved a varenicline shortage.

Results: Among the 32 included cases, the reported adverse effects were: smoking relapse (n=21), tobacco cessation failure (n=7) and tobacco withdrawal syndrome (n=2). Most of the patients presented a high level of tobacco dependence. Before the introduction of varenicline, these smokers consumed a median of 20 cigarettes per day. They did not smoke while receiving varenicline. After the shortage, the daily cigarette consumption went up to 10 in all patients treated with nicotine replacement therapy (NRT) and up to 20 when NRT was not used.

Discussion: In the context of a varenicline shortage, the pharmacovigilance data confirmed the risk of smoking relapse and/or cessation failure in patients with a strong addiction to cigarettes. Given the role of smoking exposure in respiratory, cancer and cardiovascular risk, it is vitally important that the availability of this medicine is ensured. Solutions, such as the importation of alternatives produced by other brands that pass the tests for impurity quantification, may prevent the risk in this context.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapie
Therapie 医学-药学
CiteScore
3.50
自引率
7.70%
发文量
132
审稿时长
57 days
期刊介绍: Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
期刊最新文献
Blood glutamate levels in major depression with antidepressants and benzodiazepines: A 6-month prospective cohort study. Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact. Rapid desensitization to insulin in a patient with diabetic ketoacidosis and insulin allergy. Preventing shingles starts with vaccinating against chickenpox. Reintroduction of cotrimoxazole in a Stevens-Johnson case with other antibacterial sulfonamide (sulfadiazine) among suspects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1